Refine by
Clinical Microbiology Articles & Analysis
22 news found
About Advanced Instruments Advanced Instruments is a global provider of scientific and analytical instruments for the bioprocessing, clinical and food and beverage industries. The company’s innovations have helped organizations improve quality of results, achieve reliable outcomes, and increase workplace productivity for more than 65 years. ...
Initial topline data from the study were included in a presentation at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022) on April 25, 2022. ...
Recent studies conducted on the efficacy and time-saving benefits of the Arc study will be presented at the upcoming 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022). The Arc is currently intended for Research Use Only and is not for use in diagnostic procedures. ...
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that three Idylla™ study posters, of which two on the SeptiCyte® RAPID (developed in collaboration with Immunexpress) and one on the Idylla™ SARS-CoV-2 Test (CE-IVD) and Idylla™ SARS-CoV-2/Flu/RSV Panel (CE-IVD), ...
“On the heels of publishing robust data at the 32nd European Congress for Clinical Microbiology and Infectious Diseases demonstrating the value of using the automated Accelerate Arc Module and BC kit, we’re excited to announce this product is now registered as an IVD with the FDA, and will soon be available to healthcare facilities in the U.S. ...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, presented the sub-group analysis from its Phase 2, SG016 study on Saturday 23 April in an oral presentation at the 32nd European Congress of Clinical Microbiology & Infectious ...
Today we announced the release of new performance data across two studies for the Accelerate Arc module and BC kit at the 32nd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) located in Lisbon, Portugal 23-26 April 2022. ...
(NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation (“CF Foundation”). ...
ByBiomX
The study, funded by the EU commission, has been published in Clinical Microbiology and Infection. In the AutoPilot study, the high diagnostic performance of the host-response protein signature underlying MeMed’s technology was validated in a broad pediatric cohort (n=1,008; >90 days to 18 years). ...
ByMeMed
"John knows how to sell innovation, and clinical value – two essential elements to drive change in the 'rapid AST' market that Selux is poised to disrupt." ...
Having recently completed its first clinical trial and submitted the results to the U.S. Food and Drug Administration (FDA), Selux will use the NIH grant to fund three projects that advance the commercial readiness of the Selux NGP platform. ...
Specific Diagnostics announces today the commencement of its US clinical studies for the Reveal Rapid AST System for blood infection. Trials will entail 3 months of data collection followed by submission for FDA consideration of 510(k) clearance of the Reveal test. ...
Selux's NGP platform provides unprecedented speed-to-results and breadth of menu while meeting the accuracy, throughput, and cost effectiveness requirements of clinical microbiology laboratories and integrated healthcare systems. ...
Selux's NGP platform provides unprecedented speed-to-results and breadth of menu while meeting the accuracy, throughput, and cost effectiveness requirements of clinical microbiology laboratories and integrated healthcare systems. ...
The first study, led by Dr. Martin Rottman, Professor of Clinical Microbiology at Université de VersaillesSt Quentin and Director of the Innovative Biomarkers Platform at Assistance Publique - Hôpitaux de Paris, France, was carried out at Hôpital Raymond Poincaré. ...
In Patients Who Receive Ineffective Empirical Antibiotics for Blood Stream Infections (BSI), Use of AXDX Was Associated With Reduction in 30-Day Mortality Interim Data From Multicenter Study Highlight the Real-World Clinical Utility of Fast Phenotypic Antimicrobial Susceptibility Testing for BSI Across Diverse Healthcare Settings and Patient Populations Accelerate ...
“The 5-mRNA classifier for CoVerity was developed on a training set of more than 20 clinical studies and we intend to translate it into a rapid assay that can be used as a clinical tool to help triage patients after diagnosis with COVID-19. ...
Selux will use the additional funding to advance the development of their Next Generation 'Phenotyping' (NGP) technology, a rapid and precise antimicrobial susceptibility test (AST), through clinical trials. "BARDA has offered strong support in the development of the Selux NGP platform and has led the way in the successful government-private sector collaboration to solve one of ...
Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat superbug infections and combat antimicrobial resistance, today announced it will host an integrated symposium on aspects that impact antimicrobial resistance, rapid diagnostics and clinical care at this spring's 2020 European Congress of Clinical Microbiology ...
The poster describes results from a clinical sample trial performed with Drs. Mary Jane Ferraro and Virginia Pierce of the Massachusetts General Hospital. ...